TB-500
Thymosin beta-4 fragment discussed for recovery support, with overall limited human evidence.
PreclinicalUnapprovedInjectableRecovery
Key facts
Common routesSubcutaneous, intramuscular
Half-life2-3 days (community estimate)
Typical range2-5 mg/week
Summary
TB-500 is marketed as a synthetic fragment of thymosin beta-4 and is commonly discussed for tissue recovery and resilience. For TB-500 itself, controlled human evidence remains thin; much of the conversation relies on animal data, mechanism hypotheses, and anecdotal reports.
This page summarizes the current research landscape; benefit and risk framing should stay conservative.
Mechanism notes
Cell migration and repair signaling
Thymosin beta-4 related research describes effects on actin dynamics, cell migration, and wound-repair pathways. Direct translation to TB-500 in humans remains uncertain.
Inflammation and tissue response
Preclinical models suggest possible effects on inflammatory tone and repair environment. Strong RCT data for human musculoskeletal outcomes is lacking.
Dosing patterns
Loading and repair phases
Community protocols are often discussed around 2-5 mg per week split across 1-3 injections.
This is not a clinical standard, only observed practice with high variability.
Maintenance approaches
Some users shift to less frequent injections after loading phases. Efficacy and safety of these patterns are not well validated.
Evidence snapshot
Evidence for TB-500 itself is mostly preclinical. Human studies more often involve full-length thymosin beta-4 or different indications (e.g., wound settings), which limits direct extrapolation.
Preclinical signal
Animal and mechanistic work suggests pro-repair signals, but does not provide a reliable human effect size.
Human signal
High-quality interventional data for TB-500 is missing; available human literature primarily evaluates TB4.
Safety considerations
Because TB-500 is not an approved human medicine, product quality, purity, and long-term safety remain key uncertainties.
Common cautions
- No FDA-approved TB-500 drug product for human treatment
- Variable quality and purity in unregulated peptide supply
- Prohibited in tested sport under WADA S2 (thymosin-β4 derivatives)